A 2026 RFP response brief for HR, CHROs, and CFOs evaluating wellness vendor exposure.
The Forcing Event
On April 30, 2026, the FDA published a Federal Register proposal to add semaglutide and tirzepatide to the 503B Bulks List exclusion. If finalized, large-scale compounded GLP-1 supply through 503B outsourcing facilities would end. The 60-day public comment period closes June 29, 2026.
For HR buyers running GLP-1-heavy benefits programs through telehealth platforms (eMed, MEDVi, TWC, Henry Meds, Mochi), this is structural risk you must surface in any 2026 RFP.
Vendor Exposure to the Apr 30 Proposal
Brand-name telehealth (Ro, Hims, Sesame): Low exposure — sources brand-name through standard pharmacies. eMed, MEDVi, TWC, Henry Meds, Mochi: High exposure — compounded GLP-1 = significant revenue share. In-clinic concierge: Variable — depends on 503A vs 503B sourcing. Bright Enterprises Hybrid Model: None — does not prescribe GLP-1; coordinates with patient’s prescribing clinician.
What the Bright Enterprises Hybrid Model Is
A DAOM-led integrative metabolic-support program that does NOT prescribe GLP-1 medications. We dispense the integrative oral nutraceutical layer (Pendulum Akkermansia, Quicksilver GLP-1 Amplifier, custom Chinese herbal formulas), provide acupuncture and electroacupuncture for autonomic and gut-brain axis support, and coordinate with each employee’s existing prescribing clinician for the medication side. When an employee starts, transitions, tapers, or pauses GLP-1 therapy, the integrative layer holds them steady.
Why This Survives the Apr 30 Proposal Structurally
1. No prescription dependency. Our clinical work does not depend on compounded GLP-1 supply. If the proposal finalizes, our model continues unchanged.
2. Outcome-tracked, not medication-tracked. Our success metrics are biomarker movement (hsCRP, HRV, salivary cortisol, body composition, sleep architecture), not prescription continuity.
3. Coordinated, not consolidated. We are the integrative-specialty layer alongside existing PCPs, concierge MDs, OB-GYNs. That coordination architecture insulates the model.
What Bright Enterprises Hybrid Model Includes
- C-suite + senior-operator cohort focus (5–25 employees; sized for high-leverage individuals)
- CEO Cortisol Audit framework — 90-day HPA-axis quantification + intervention + re-measure
- Integrative metabolic-support layer — DAOM-dispensed nutraceuticals, custom herbal formulas, acupuncture, electroacupuncture
- Coordination with each employee’s prescribing clinicians — quarterly clinical syntheses, direct provider communication
- Biomarker-tracked outcomes — pre/post cortisol, HRV, hsCRP, body composition, sleep architecture, hormone panels
- Layered, not replacement — drops in alongside Wellable, Limeade, Virgin Pulse, or existing engagement programs
- Federal-regulatory clinical authority — Dr. Bright is filing a formal comment to the FDA 503B GLP-1 docket (FDA-2018-N-3240) by May 26, 2026 as a clinician-voice DAOM/Functional Medicine practitioner. This citation lives in Federal Register history and signals to your CFO/compliance team that the vendor’s clinical authority extends to federal regulatory engagement, not just patient-facing care.
Pricing Structure for HR Buyers
Two tiers (per employee per year, cash-pay through HR with HSA/FSA-eligible portions per employee with proper documentation):
Employee Tier: $2,000/employee/year — 90-min initial intake + 6 flexible sessions/year (Functional Medicine, supplements, peptides, acupuncture, hypnotherapy, NET) + 2 full blood labs/year + direct clinician access for monitoring questions.
Executive Tier: $10,000/employee/year — Everything in Employee Tier + 16 sessions/year (instead of 6) + 4 specialty tests/year (DUTCH + GI-MAP + OAT + mycotoxin/heavy metals) + epigenetic aging clocks (PhenoAge, GrimAge, DunedinPACE) + neuro-cognitive enhancement protocols (peptides, nootropic stacks, sleep architecture) + 90-Day CEO Cortisol Audit framework + priority same-week scheduling + travel-friendly supplement and peptide formulations.
Bundled enterprise pricing for 5+ cohorts. HSA/FSA-eligible on most line items with Letter of Medical Necessity.
Why the Function Health × SuppCo Acquisition (May 12, 2026) Reinforces This Model
On May 12, 2026, Function Health acquired SuppCo — a supplement-rating + curation platform. The strategic signal: D2C longevity-tracking platforms are consolidating up the stack into clinical territory (lab interpretation + AI protocols + supplement guidance) to defend their consumer subscription economics.
For HR buyers evaluating wellness vendors in 2026, this consolidation pattern matters for three reasons:
1. D2C consolidation does not solve the in-network model problem. Function + SuppCo is still a consumer subscription product. The HR buyer who wants their workforce on a consolidated wellness platform still has the question of where the clinical care happens when their employees need it — and consumer D2C platforms don’t fill that gap.
2. The clinical-pipeline + hybrid-DAOM model is structurally distinct from D2C consolidation. Bright Enterprises hybrid model layers integrative-specialty care (with credentialed clinician on-the-ground in OC) alongside the employee’s existing primary-care relationship. We are not a D2C platform; we are a clinical service. The acquisition activity in the D2C space doesn’t constrain our model.
3. Supplement-specificity from D2C platforms doesn’t replace clinical supplement guidance. SuppCo’s rating system is consumer-facing — it tells the consumer which supplements rank well across broad criteria. Clinical supplement protocols require lab-integrated, patient-specific, peptide-interaction-aware, paradigm-aware brand selection. That’s the work Bright Enterprises does in the Employee + Executive Tier — and it’s not what Function × SuppCo is.
For the HR RFP, the question isn’t “should we get a consumer-grade longevity platform?” It’s “should we layer outcome-tracked clinical care for the cohorts whose biomarkers actually matter to the company?” Those are different products.
Three Questions to Ask in Your Vendor Audit This Quarter
1. Where does your current GLP-1 vendor source medication — 503A, 503B, or brand-name? If 503B or unclear, you have exposure. 2. What is their contingency plan if the Apr 30 proposal finalizes? 3. What is their integrative metabolic-support layer that holds employees steady through any GLP-1 supply disruption?
How to Pilot the Bright Enterprises Hybrid Model
90-Day C-Suite Pilot — drop-in alongside existing program. Cohort: 5–15 senior-operator employees. Pre/post measurement: cortisol, HRV, hsCRP, sleep, body composition, hormone panels. Intervention: CEO Cortisol Audit + integrative metabolic-support. Deliverable: end-of-pilot biomarker delta + 12-month maintenance protocol. Cost: $2,250 pilot fee + continuation $2,000–$10,000 per executive per year depending on tier. Geography: Newport Beach + telehealth. No rip-and-replace. No vendor lock-in.
Next Steps
1. 15-minute discovery call to scope exposure to Apr 30 503B proposal. 2. 90-Day C-Suite Pilot scoping document. 3. Monthly cohort onboarding, capacity-capped.
Contact: brandonbright@gmail.com
Dr. Brandon Bright, DAOM, LAc
Holistic and integrative medicine practitioner serving Tustin and patients nationwide.